CRVO
CervoMed Inc. NASDAQ Listed May 23, 2008$4.24
+11.29%
vs $3.81
Mkt Cap $38.3M
52w Low $2.25
23.6% of range
52w High $10.69
50d MA $3.48
200d MA $6.02
P/E (TTM)
-1.4x
EV/EBITDA
—
P/B
2.1x
Debt/Equity
0.0x
ROE
-148.0%
P/FCF
-1.6x
RSI (14)
62.40
ATR (14)
$0.83
Beta
-5.04
50d MA
$3.48
200d MA
$6.02
Avg Volume
10.9M
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CIK (SEC)
Phone
617-744-4400
20 Park Plaza · Boston, MA 02116 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | AMC | -0.79 | -0.86 | -8.5% | 3.44 | -2.6% | -11.6% | -4.9% | +12.1% | -4.6% | -1.0% | — |
| Mar 13, 2026 | AMC | -0.79 | -0.88 | -11.4% | 4.25 | +0.5% | +1.4% | +5.1% | -6.4% | -0.2% | -5.0% | — |
| Nov 7, 2025 | AMC | -0.68 | -0.84 | -23.5% | 6.92 | -2.3% | -0.3% | +1.0% | +6.3% | -2.2% | +5.9% | — |
| Aug 8, 2025 | AMC | -0.57 | -0.70 | -22.8% | 9.85 | +1.1% | -3.6% | -1.1% | +2.6% | +5.7% | -0.7% | — |
| May 12, 2025 | AMC | -0.60 | -0.56 | +6.7% | 9.10 | -2.6% | -4.4% | -4.4% | +3.8% | +1.6% | +0.1% | — |
| Mar 17, 2025 | AMC | -0.67 | -0.80 | -19.4% | 9.05 | +7.5% | +3.2% | +0.3% | +23.4% | +23.6% | -25.1% | — |
| Nov 12, 2024 | AMC | -0.41 | -0.55 | -34.1% | 11.83 | +1.0% | -5.2% | -2.7% | -1.4% | -3.3% | -3.2% | — |
| Aug 9, 2024 | AMC | -0.24 | -0.27 | -12.5% | 11.28 | -3.9% | +7.5% | +23.7% | +13.6% | +0.0% | +7.2% | — |
| May 14, 2024 | AMC | -0.46 | -0.41 | +10.9% | 24.70 | +3.9% | +0.1% | -1.5% | -1.1% | -18.1% | -1.5% | — |
| Mar 25, 2024 | AMC | -0.29 | -0.38 | -31.0% | 21.08 | +2.5% | -1.4% | -5.6% | +18.8% | -2.6% | -2.4% | — |
| Nov 13, 2023 | AMC | -0.95 | -0.70 | +26.3% | 9.73 | +0.3% | -1.4% | +3.1% | -0.3% | +0.1% | -0.5% | — |
| Aug 8, 2023 | AMC | -2.90 | -1.04 | +64.1% | 4.89 | -3.1% | -3.7% | +11.9% | -1.1% | +5.2% | +7.8% | — |
| May 15, 2023 | AMC | -2.87 | -3.01 | -5.0% | 5.96 | +0.0% | -3.4% | -1.0% | +1.4% | +3.6% | +3.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $3.96 | +0.5% | -2.3% | +0.8% | -1.5% | -2.9% | -1.6% |
| Apr 22 | D. Boral Capital | Maintains | Buy → Buy | — | $3.89 | $4.00 | +2.8% | +1.3% | -2.3% | +0.8% | -1.5% | -2.9% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $3.84 | $3.90 | +1.6% | +5.2% | -0.2% | -5.0% | +4.7% | +0.7% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $4.24 | $4.23 | -0.2% | -0.2% | -5.0% | +0.0% | -2.5% | +3.1% |
| Mar 18 | Roth Capital | Maintains | Buy → Buy | — | $4.53 | $4.55 | +0.4% | -6.4% | -0.2% | -5.0% | +0.0% | -2.5% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $4.53 | $4.55 | +0.4% | -6.4% | -0.2% | -5.0% | +0.0% | -2.5% |
| Mar 16 | D. Boral Capital | Maintains | Buy → Buy | — | $4.25 | $4.27 | +0.5% | +1.4% | +5.1% | -6.4% | -0.2% | -5.0% |
| Mar 5 | Chardan Capital | Maintains | Buy → Buy | — | $4.02 | $4.07 | +1.2% | -0.2% | +2.5% | +10.5% | +7.0% | -9.1% |
| Mar 4 | D. Boral Capital | Maintains | Buy → Buy | — | $4.01 | $4.23 | +5.5% | +0.2% | -0.2% | +2.5% | +10.5% | +7.0% |
| Feb 18 | D. Boral Capital | Maintains | Buy → Buy | — | $4.54 | $4.75 | +4.6% | +8.6% | +6.1% | -11.5% | +0.2% | +3.2% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.99 | $8.10 | +1.4% | -1.1% | -3.8% | +6.8% | +3.7% | +0.7% |
| Dec 5 | D. Boral Capital | Maintains | Buy → Buy | — | $9.06 | $9.21 | +1.7% | -4.1% | +1.2% | -1.8% | +0.5% | -5.5% |
| Dec 2 | D. Boral Capital | Maintains | Buy → Buy | — | $9.22 | $9.32 | +1.1% | -10.8% | +0.7% | +9.4% | -4.1% | +1.2% |
| Nov 11 | D. Boral Capital | Maintains | Buy → Buy | — | $6.90 | $6.82 | -1.2% | +1.0% | +6.3% | -2.2% | +5.9% | +6.9% |
| Nov 5 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $7.02 | $7.54 | +7.4% | +4.6% | -0.7% | -5.1% | -0.3% | +1.0% |
| Nov 4 | D. Boral Capital | Maintains | Buy → Buy | — | $7.02 | $7.06 | +0.6% | +0.0% | +4.6% | -0.7% | -5.1% | -0.3% |
| Sep 8 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.51 | $10.51 | +0.0% | -4.9% | +0.1% | -4.8% | -3.4% | -3.8% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $10.12 | $10.48 | +3.6% | -2.9% | -6.9% | +0.9% | -0.1% | -1.0% |
| Aug 12 | Roth Capital | Maintains | Buy → Buy | — | $9.50 | $9.64 | +1.5% | -1.1% | +2.6% | +5.7% | -0.7% | -2.9% |
| Aug 11 | D. Boral Capital | Maintains | Buy → Buy | — | $9.85 | $9.96 | +1.1% | -3.6% | -1.1% | +2.6% | +5.7% | -0.7% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.85 | $9.96 | +1.1% | -3.6% | -1.1% | +2.6% | +5.7% | -0.7% |
| Jul 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.67 | $8.95 | +3.2% | -2.9% | +1.0% | -2.9% | +7.0% | +5.7% |
| Jul 28 | D. Boral Capital | Maintains | Buy → Buy | — | $8.98 | $12.04 | +34.1% | -3.5% | -2.9% | +1.0% | -2.9% | +7.0% |
| Jul 25 | D. Boral Capital | Maintains | Buy → Buy | — | $8.05 | $8.01 | -0.5% | +11.6% | -3.5% | -2.9% | +1.0% | -2.9% |
| Jun 11 | D. Boral Capital | Maintains | Buy → Buy | — | $7.72 | $7.85 | +1.7% | -3.2% | +2.0% | -6.6% | +2.0% | -2.8% |
| May 13 | D. Boral Capital | Maintains | Buy → Buy | — | $9.10 | $8.86 | -2.6% | -4.4% | -4.4% | +3.8% | +1.6% | +0.1% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $8.49 | $8.77 | +3.3% | +7.2% | -4.4% | -4.4% | +3.8% | +1.6% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $8.85 | $8.80 | -0.6% | -12.9% | +10.2% | +11.5% | -3.5% | +9.1% |
| Mar 18 | Roth MKM | Maintains | Buy → Buy | — | $9.05 | $9.73 | +7.5% | +3.2% | +0.3% | +23.4% | +23.6% | -25.1% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $9.05 | $9.73 | +7.5% | +3.2% | +0.3% | +23.4% | +23.6% | -25.1% |
| Mar 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.05 | $9.73 | +7.5% | +3.2% | +0.3% | +23.4% | +23.6% | -25.1% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $6.44 | $7.07 | +9.8% | +40.5% | +3.2% | +0.3% | +23.4% | +23.6% |
| Mar 13 | Chardan Capital | Upgrade | Neutral → Buy | — | $6.17 | $7.79 | +26.3% | -6.2% | +11.2% | +40.5% | +3.2% | +0.3% |
| Mar 13 | Jones Trading | Upgrade | Hold → Buy | — | $6.17 | $7.79 | +26.3% | -6.2% | +11.2% | +40.5% | +3.2% | +0.3% |
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $2.22 | $2.16 | -2.7% | +6.3% | +161.4% | -6.2% | +11.2% | +40.5% |
| Mar 11 | Roth MKM | Maintains | Buy → Buy | — | $2.22 | $2.16 | -2.7% | +6.3% | +161.4% | -6.2% | +11.2% | +40.5% |
| Feb 19 | D. Boral Capital | Upgrade | Hold → Buy | — | $2.23 | $2.28 | +2.2% | +3.1% | +1.3% | -2.1% | -1.8% | -3.1% |
| Dec 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.95 | $1.87 | -4.1% | -0.5% | +3.1% | +11.5% | +0.0% | -0.9% |
| Dec 11 | Chardan Capital | Downgrade | Buy → Neutral | — | $2.16 | $2.15 | -0.5% | -9.7% | -1.0% | -1.6% | +2.6% | -0.5% |
| Dec 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.16 | $2.15 | -0.5% | -9.7% | -1.0% | -1.6% | +2.6% | -0.5% |
| Dec 10 | Jones Trading | Downgrade | Buy → Hold | — | $10.25 | $2.53 | -75.3% | -78.9% | -9.7% | -1.0% | -1.6% | +2.6% |
| Dec 10 | D. Boral Capital | Downgrade | Buy → Hold | — | $10.25 | $2.53 | -75.3% | -78.9% | -9.7% | -1.0% | -1.6% | +2.6% |
| Nov 27 | D. Boral Capital | Maintains | Buy → Buy | — | $7.98 | $8.54 | +7.0% | +14.7% | +18.0% | -2.9% | -1.0% | -6.6% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $11.22 | $11.46 | +2.1% | -2.7% | -1.4% | -3.3% | -3.2% | -4.4% |
| Jul 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.85 | $14.93 | +0.5% | -3.2% | -2.4% | +2.7% | -3.6% | -6.4% |
| Apr 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $20.50 | $21.04 | +2.6% | +13.1% | -0.2% | +5.7% | +3.0% | -0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | BOGER JOSHUA SDir | — | Buy | 955,414 | $3.14 | $3.0M | 1,795,865 | +82.26% | — |
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
Jun 18
8-K · 7.01
! Medium
CervoMed Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 15
8-K · 1.01
!! High
CervoMed Inc. -- 8-K 1.01: Material Agreement
Jun 10
8-K
CervoMed Inc. -- 8-K Filing
Jun 9
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed presented clinical data at the American Academy of Neurology conference, incorporating key findings into its SEC filing to highlight potentially significant trial results for investors.
Apr 22
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CervoMed's presentation of positive neflamapimod clinical findings and finalized Phase 3 trial design signals advancement toward a potentially valuable dementia treatment, which could drive stock appreciation if trial results prove successful.
Apr 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Crescent Robotics disclosed information via Regulation FD that isn't legally binding and won't affect existing SEC filings, so investors should disregard this as non-material disclosure.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CRVO's biomarker analysis showing stronger treatment effects in lower tau patients could support a narrower, higher-probability approval pathway, potentially de-risking future regulatory decisions and improving stock valuation.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cerevel Therapeutics disclosed material non-public information to select parties, potentially signaling upcoming news that could impact stock valuation before public announcement.
Mar 17
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed's incorporation of its March 4, 2026 press release details into an 8-K filing indicates a material corporate event requiring SEC disclosure, though the specific announcement details require reviewing the referenced press release.
Mar 4
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed Inc. disclosed material information through a February 18, 2026 press release, incorporated into this 8-K filing, though specific details require reviewing the referenced press release for investor impact assessment.
Feb 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 948,988 | $7M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 316,202 | $1M | New | Mar 2026 |
| 3 | Millennium Management | 208,908 | $823K | Added | Mar 2026 |
| 4 | Renaissance Technologies Llc | 63,904 | $252K | New | Mar 2026 |
| 5 | Citizens Financial Group Inc/ri | 37,477 | $148K | — | Mar 2026 |
| 6 | Northern Trust Corp | 30,044 | $118K | Reduced | Mar 2026 |
| 7 | Hightower Advisors, Llc | 11,244 | $89K | — | Dec 2025 |
| 8 | Jane Street Group, Llc | 11,076 | $88K | New | Dec 2025 |
| 9 | Russell Investments Group, Ltd. | 16,090 | $63K | — | Mar 2026 |
| 10 | Byrne Asset Management Llc | 14,700 | $58K | — | Mar 2026 |
| 11 | Fmr Llc | 11,040 | $43K | Reduced | Mar 2026 |
| 12 | Thompson Davis & Co., Inc. | 10,000 | $39K | — | Mar 2026 |
| 13 | Ubs Group Ag | 5,239 | $21K | Added | Mar 2026 |
| 14 | Federation Des Caisses Desjardins Du Quebec | 1,700 | $7K | New | Mar 2026 |
| 15 | Wfa Of San Diego, Llc | 725 | $3K | — | Mar 2026 |
| 16 | Tsfg, Llc | 300 | $2K | — | Dec 2025 |
| 17 | Royal Bank Of Canada | 283 | $1K | New | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 91 | $359 | — | Mar 2026 |
| 19 | Cwm, Llc | 39 | $154 | Reduced | Mar 2026 |
| 20 | Arax Advisory Partners | 14 | $20 | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 32,663 | $130K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 17,475 | $69K | Mar 2026 |
| 3 | U.S. SMALL CAP PORTFOLIO | 8,875 | $46K | Jan 2026 |
| 4 | Fidelity Total Market Index Fund | 9,020 | $36K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 7,734 | $31K | Feb 2026 |
| 6 | U.S. MICRO CAP PORTFOLIO | 4,951 | $25K | Jan 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 4,911 | $20K | Feb 2026 |
| 8 | Small Cap Core Fund | 3,978 | $16K | Mar 2026 |
| 9 | Avantis U.S. Small Cap Equity ETF | 3,281 | $13K | Feb 2026 |
Valuation
Market Cap
$38.3M
Enterprise Value
$17.5M
P/E (TTM)
-1.42x
Forward P/E
—
PEG Ratio
-0.06x
P/B
2.10x
P/S
9.57x
P/FCF
-1.63x
EV/EBITDA
—
Shares Out
9.0M
Financials (TTM)
Revenue
$4.0M
Net Income
-$27.0M
EBITDA
-$28.3M
Free Cash Flow
-$23.4M
Op Cash Flow
-$23.4M
EPS Basic
$-2.98
EPS Diluted
$-2.98
EPS Forward
$-2.35
Gross Margin
0.0%
Op Margin
-706.2%
Net Margin
-673.1%
Balance Sheet
Total Assets
$23.4M
Total Liab.
$5.2M
Total Equity
$18.2M
Cash
$20.9M
LT Debt
$0
Book Value/Sh
$2.02
Debt/Equity
0.00x
Current Ratio
4.84
Quick Ratio
4.84
Returns & Growth
ROE
-148.0%
ROA
-117.9%
ROIC
-151.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-47.5%
Price Returns
2W
-17.3%
1M
-15.7%
3M
-22.1%
6M
-68.7%
12M
-56.9%
Technicals
52W High
$10.69
52W Low
$2.25
50d MA
$3.48
200d MA
$6.02
RSI (14)
62.40
ATR (14)
$0.83
Beta
-5.04
Avg Volume
10.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$25.00
High
$25.00
Low
$25.00
Median
$25.00
Data updated apr 25, 2026 3:24am
· Source: financialmodelingprep.com